secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001654954-24-010278
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics closes $100M private placement to fund Phase 3 levosimendan program
--------------------------------------------------------------------------------

- Gross proceeds of ~$100M from oversubscribed private placement led by BVF Partners.
- Issued 1,450,661 common shares at $3.00, plus pre-funded warrants for 31,882,671 shares and warrants for 16,666,666 shares.
- Funds will complete ongoing LEVEL Phase 3 study and initiate a second Phase 3 study in 2025, shortening NDA timeline.
- Oral levosimendan (TNX-103) targets PH-HFpEF, a disease with no approved therapies; earlier HELP study showed 29-meter 6MWD improvement.
- Leerink Partners, Guggenheim Securities, and William Blair acted as placement agents; ROTH Capital advised Tenax.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495424010278/0001654954-24-010278-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495424010278/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-010278

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer